References
- White PT , CohenMS. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin. Drug Discov.10(4), 427–439 (2015).
- Casadei Gardini A , ChiadiniE , FaloppiLet al. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer16(1), 429 (2016).
- Guidetti A , Carlo‐StellaC , LocatelliSLet al. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br. J. Haematol.158(1), 108–119 (2012).
- Morgillo F , CasconeT , D’AiutoEet al. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br. J. Cancer105(3), 382–392 (2011).
- Spigel DR , RubinMS , GianVGet al. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small-cell lung cancer progressing on erlotinib: a randomized Phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer113, 79–84 (2017).
- Paz-Ares L , HirshV , ZhangLet al. Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) trial: a Phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J. Thorac. Oncol.10(12), 1745–1753 (2015).
- Scagliotti G , NovelloS , von PawelJet al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol.28(11), 1835–1842 (2010).
- Yu H , SteeghsN , NijenhuisCM , SchellensJHM , BeijnenJH , HuitemaADR. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin. Pharmacokinet.53(4), 305–325 (2014).
- Park SY , KangZ , ThapaPet al. Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach. Int. J. Pharm.566, 229–238 (2019).
- Truong DH , TranTH , RamasamyTet al. Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib. Powder Technol.283, 260–265 (2015).
- Giglio V , VialeM , BertoneV , MaricI , VaccaroneR , VecchioG. Cyclodextrin polymers as nanocarriers for sorafenib. Invest. New Drugs36(3), 370–379 (2018).
- Feczkó T , MerzaG , BabosGet al. Preparation of cubic-shaped sorafenib-loaded nanocomposite using well-defined poly(vinyl alcohol alt-propenylene) copolymer. Int. J. Pharm.562, 333–341 (2019).
- Xu X , HoW , ZhangX , BertrandN , FarokhzadO. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med.21(4), 223–232 (2015).
- Desai N . Challenges in development of nanoparticle-based therapeutics. AAPS J.14(2), 282–295 (2012).
- Tran S , DeGiovanniP-J , PielB , RaiP. Cancer nanomedicine: a review of recent success in drug delivery. Clin. Transl. Med.6(1), 44 (2017).
- Benizri S , FereyL , AliesBet al. Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res. Lett.13(1), 17 (2018).
- Garbuzenko OB , MainelisG , TaratulaO , MinkoT. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol. Med.11(1), 44–55 (2014).
- Minko T , Rodriguez-RodriguezL , PozharovV. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv. Drug Deliv. Rev.65(13–14), 1880–1895 (2013).
- Ahmad J , AkhterS , RizwanullahMet al. Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci. Appl.8, 55–66 (2015).